Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Novartis MenB recombinant vaccine and single-dose MenACWY conjugate vaccine in healthy at-risk adults
2007-001563-29Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of meningococcal group B vaccine (recombinant, adsorbed) and Meningococcal ACWY conjugate vaccine in meningococcal disease, sponsored by Novartis. Primary endpoints: Immunogenicity of MenACWY conjugate vaccine, Safety and tolerability and 1 more. Started May 2007; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2007-001563-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001563-29.